MRNA - Moderna

-

$undefined

N/A

(N/A)

Moderna NasdaqGS:MRNA Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Location: 325 Binney Street, Cambridge, MA, 02142, United States | Website: https://www.modernatx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

5.185B

Cash

5.975B

Avg Qtr Burn

-763M

Short % of Float

18.64%

Insider Ownership

7.28%

Institutional Own.

73.87%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Approved

Quarterly sales

mRESVIA (mRNA-1345) Details
Respiratory syncytial virus

PDUFA

Approval decision

PDUFA

Approval decision

mRNA-1083 Details
COVID-19, Influenza

BLA

Resubmission

BLA

Submission

Phase 3

Data readout

mRNA-4157/V940 +KEYTRUDA Details
Cancer, Non-small cell lung carcinoma

Phase 3

Data readout

mRNA-1403 Details
Norovirus, Gastroenteritis

Phase 3

Data readout

mRNA-1647 Details
Cytomegalovirus

Phase 3

Data readout

mRNA-3705 Details
Rare diseases, Methylmalonic acidemia

Phase 3

Initiation

mRNA-1468 Details
Varicella-zoster virus

Phase 1/2

Data readout

mRNA-3927 Details
Propionic acidemia

Phase 1/2

Update

mRNA-1018 Details
H5N1 avian influenza

Phase 1/2

Update

mRNA-1574 Details
Human immunodeficiency virus

Phase 1

Data readout